Treatment options for refractory B-cell lymphoma have evolved dramatically in recent years, offering new hope for patients whose disease doesn’t respond to standard therapy or comes back after initial treatment. Understanding these options can help patients navigate this challenging journey.

When Lymphoma Doesn’t Respond: A New Era of Treatment Choices

For many patients with B-cell lymphoma, the journey doesn’t end with the first round of treatment. Some people find that their disease doesn’t respond as expected, or it returns after a period of improvement. When this happens, medical teams have more tools at their disposal than ever before. The goal of treating refractory B-cell lymphoma is to control the disease, manage symptoms, and improve quality of life, while carefully considering each patient’s individual situation and overall health.^[2]

Around 40% of patients with diffuse large B-cell lymphoma—a common form of aggressive B-cell lymphoma—face either refractory disease (meaning the cancer doesn’t respond to initial treatment) or relapse (when the disease returns after a period of remission). Refractory disease affects about 15 to 20% of patients, while another 20 to 30% experience relapse after their first line of treatment. These numbers highlight the importance of having effective second-line and third-line treatment options available.^[2][7]

Treatment decisions depend on several factors, including when the disease stopped responding or came back, whether the patient is healthy enough for intensive therapies like stem cell transplantation, and the specific characteristics of the lymphoma. Before starting a new round of treatment, doctors often recommend repeating a biopsy—a procedure to remove a small sample of tissue for testing—to confirm the diagnosis and rule out other conditions that might appear similar on imaging scans.^[7]

Standard Treatment Approaches for Refractory B-cell Lymphoma

When B-cell lymphoma doesn’t respond to initial therapy or returns after treatment, doctors turn to second-line treatment options that are more intensive than the first round. One of the most established approaches is high-dose chemotherapy followed by stem cell transplantation, a procedure that replaces damaged stem cells with healthy ones capable of producing new blood cells.^[1]

Most patients who undergo stem cell transplantation receive an autologous transplant, meaning they receive their own stem cells that were collected and stored before the high-dose chemotherapy. This process helps the body recover from the intensive treatment by providing fresh stem cells that can rebuild the blood and immune system. Less commonly, some patients may undergo an allogeneic transplant, where stem cells come from a matched donor.^[1]

For patients whose disease has relapsed or proven refractory, several combination chemotherapy regimens are available as second-line options. These include ICE, which combines the drugs ifosfamide, carboplatin, and etoposide. Another option is DHAP, which uses dexamethasone, cisplatin, and cytarabine together. Doctors may also use gemcitabine-based therapy, which includes a drug that interferes with cancer cell growth.^[1][6]

Beyond traditional chemotherapy combinations, several newer targeted medications have been approved for relapsed or refractory B-cell lymphoma. Bendamustine, sold under the brand name Treanda, is often combined with rituximab (Rituxan), a monoclonal antibody that targets a specific protein called CD20 on the surface of B-cells. Similarly, lenalidomide (Revlimid) can be paired with rituximab to enhance the immune system’s ability to fight cancer cells.^[1]

More advanced targeted therapies include polatuzumab vedotin-piiq (Polivy), which delivers chemotherapy directly to cancer cells, and selinexor (Xpovio), which blocks a protein that cancer cells need to survive. Tafasitamab-cxix (Monjuvi) is another monoclonal antibody that helps the immune system recognize and destroy lymphoma cells. The combination of polatuzumab vedotin with bendamustine and rituximab has shown effectiveness in patients who cannot undergo transplantation, as has the pairing of tafasitamab with lenalidomide.^[1][2]

Historically, the outlook for patients with refractory disease was poor, with limited treatment options beyond conventional chemotherapy. The SCHOLAR-1 study, which examined outcomes for patients with refractory disease, reported that the median overall survival was only 6.3 months for patients whose disease didn’t respond to their last line of therapy. Only about 20% of patients achieved long-term survival with autologous stem cell transplantation in the relapsed setting, as more than 80% of patients either didn’t respond well enough to second-line chemotherapy or weren’t healthy enough to undergo transplantation.^[8]

Breakthrough Immunotherapies in Clinical Practice

One of the most significant advances in treating relapsed or refractory B-cell lymphoma has been the development and approval of CAR T-cell therapy, a form of immunotherapy that engineers a patient’s own immune cells to recognize and attack cancer cells. This approach has transformed treatment possibilities, particularly for patients who haven’t responded to other therapies.^[1]

CAR T-cell therapy works by collecting T-cells—a type of white blood cell that fights infection—from the patient’s blood. These cells are then modified in a laboratory to produce special receptors called chimeric antigen receptors (CARs) on their surface. These receptors are designed to recognize and bind to a protein called CD19, which is found on B-cells, including cancerous B-cells. Once the modified cells are infused back into the patient, they can seek out and destroy lymphoma cells throughout the body.^[8]

Three CAR T-cell therapies have been approved for relapsed or refractory B-cell lymphoma: axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah). Initially approved for use in third-line treatment or later (meaning after at least two previous treatment attempts), CAR T-cell therapy with axicabtagene ciloleucel was first approved in 2017. This therapy demonstrated an overall response rate of 82% and a complete response rate of 58%, with a five-year overall survival of 42.6%, confirming the curative potential of this cellular therapy.^[1][8]

The success of these therapies led to a major shift in treatment strategy. In 2021, CAR T-cell therapy with either axicabtagene ciloleucel or lisocabtagene maraleucel received approval for earlier use—as a second-line treatment option for patients with primary refractory disease (disease that never responded to initial treatment) or disease that relapses within 12 months. This approval was based on positive results from Phase 3 clinical trials called ZUMA-7 and TRANSFORM, which showed that CAR T-cell therapy could be more effective than the traditional approach of chemotherapy followed by stem cell transplantation for certain patients. This has made CAR T-cell therapy a new standard treatment option for patients with refractory or early relapsed disease.^[2][8]

Another category of immunotherapy that has shown promise includes bispecific antibodies—molecules designed with two different binding sites that can simultaneously attach to cancer cells and immune cells, bringing them close together so the immune system can attack the cancer. Two such therapies, epcoritamab-bysp (Epkinly) and glofitamab-gxbm (Columvi), have been approved for relapsed or refractory B-cell lymphoma.^[1][8]

For patients who have a specific type of B-cell lymphoma called primary mediastinal large B-cell lymphoma (PMBCL), which develops in the chest area, the drug pembrolizumab (Keytruda) offers another immunotherapy option. This medication is a type of checkpoint inhibitor that helps the immune system stay active against cancer cells by blocking proteins that would otherwise turn off the immune response.^[1]

Emerging Therapies and Clinical Trial Options

Beyond the therapies already approved for standard use, researchers continue to develop and test new treatments for relapsed or refractory B-cell lymphoma through clinical trials. These trials represent an important option for patients, particularly those whose disease hasn’t responded to available treatments or who are looking for potentially more effective therapies.^[8]

The landscape of clinical trials for refractory B-cell lymphoma has expanded significantly in recent years, with multiple novel therapeutic approaches being investigated. These include not only new immunotherapy strategies but also targeted therapies that work by interfering with specific molecular pathways that cancer cells need to survive and grow. The development and approval of multiple targeted therapies has added complexity to treatment selection, as doctors must now consider factors such as the mechanism of action, potential side effects, and how different treatments might be sequenced for maximum benefit.^[8]

Clinical trials testing new treatments typically progress through different phases. Phase I trials focus primarily on safety, determining what dose of a new drug can be given safely and identifying potential side effects. Phase II trials examine whether the treatment appears to be effective against the disease, measuring how many patients respond and for how long. Phase III trials compare the new treatment directly with standard treatments to determine if it offers better outcomes. Many of the therapies now approved for refractory B-cell lymphoma were tested through this rigorous process.^[8]

Patients interested in clinical trials can discuss options with their healthcare team, as eligibility depends on various factors including the specific type of lymphoma, previous treatments received, overall health status, and the specific requirements of each trial. While trials offer access to potentially promising new therapies, they also typically involve closer monitoring and more frequent visits than standard treatment approaches.^[10]

Most common treatment methods

• Stem Cell Transplantation
  • High-dose chemotherapy followed by autologous stem cell transplantation (using patient’s own stem cells collected before treatment)
  • Allogeneic transplantation (using donor stem cells) performed less commonly
  • Standard approach for eligible patients with relapsed or refractory disease
• Combination Chemotherapy Regimens
  • ICE protocol: ifosfamide, carboplatin, and etoposide
  • DHAP protocol: dexamethasone, cisplatin, and cytarabine
  • Gemcitabine-based therapy combinations
  • Bendamustine (Treanda) combined with rituximab (Rituxan)
• Targeted Antibody Therapies
  • Polatuzumab vedotin-piiq (Polivy) – delivers chemotherapy directly to cancer cells
  • Tafasitamab-cxix (Monjuvi) – monoclonal antibody that helps immune system destroy lymphoma cells
  • Lenalidomide (Revlimid) combined with rituximab – enhances immune response against cancer
  • Selinexor (Xpovio) – blocks proteins cancer cells need to survive
• CAR T-cell Therapy
  • Axicabtagene ciloleucel (Yescarta) – approved as second-line option for early relapse or refractory disease
  • Lisocabtagene maraleucel (Breyanzi) – approved for second-line treatment in specific situations
  • Tisagenlecleucel (Kymriah) – CD19-directed CAR T-cell therapy
  • Engineered patient’s own T-cells to recognize and attack cancer cells
• Bispecific Antibodies
  • Epcoritamab-bysp (Epkinly) – connects cancer cells with immune cells
  • Glofitamab-gxbm (Columvi) – brings immune cells and lymphoma cells together for attack
• Checkpoint Inhibitor Therapy
  • Pembrolizumab (Keytruda) – for patients with primary mediastinal large B-cell lymphoma subtype
  • Helps immune system stay active against cancer cells by blocking inhibitory proteins